COMMUNIQUÉS West-GlobeNewswire

Trevena to Present Phase 3, Open-Label Safety Study of Oliceridine at the American Society of Anesthesiologists Annual Meeting
12/10/2018
CHESTERBROOK, Pa., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN) today announced a poster presentation at ANESTHESIOLOGY® 2018, the national conference for the American Society of Anesthesiologists (ASA [...]
A Letter from Emblem’s President & CEO
12/10/2018
TORONTO, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV:EMC, OTCQX: EMMBF ) (" Emblem " or the " Company ") delivers strategic vision to shareholders: With adult-use legalization only days away, I am incredibly [...]
Michael DePerro, MD, Offers Minimally Invasive Gynecomastia Surgery Technique
12/10/2018
This unique approach helps reduce scarring that typically results from the procedure. COLUMBUS, Ohio, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Dr. Michael DePerro , double board-certified plastic surgeon and head of DePerro [...]
NovuHealth Named No. 5 on Minneapolis/St. Paul Business Journal's Fast 50 List for Two Years Running
12/10/2018
Company Is Top Healthcare Firm on List of the 50 Fastest-Growing Private Companies in the Twin Cities, with 230% Growth from 2015-2017 MINNEAPOLIS, Oct. 12, 2018 (GLOBE NEWSWIRE) -- NovuHealth , the healthcare industry’ [...]
Innovation Pharmaceuticals Brilacidin as a Novel Inhibitor of Phosphodiesterase 4 (PDE4) Supports its Potential to Treat Autoimmune and Inflammatory Diseases; Company Invited to Present at Upcoming Crohn’s & Colitis Foundation Conference
12/10/2018
BEVERLY, Mass., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide this update on Brilacidin as a novel [...]
RAMSAY GENERALE DE SANTE : supplement to the offer document in respect of the public offer to the shareholders of Capio
12/10/2018
PRESS RELEASE THIS PRESS RELEASE MAY NOT, DIRECTLY OR INDIRECTLY, BE DISTRIBUTED OR PUBLISHED IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, OR SOUTH AFRIC A. THE OFFER IS NOT BEING MADE TO (AND [...]
RAMSAY GENERALE DE SANTE : complément au document d'offre relatif à l'offre publique d'achat faite aux actionnaires de Capio
12/10/2018
COMMUNIQUE DE PRESSE LE PRESENT COMMUNIQUE DE PRESSE NE PEUT ETRE, DIRECTEMENT OU INDIRECTEMENT, DISTRIBUE OU PUBLIE EN AUSTRALIE, CANADA, HONG KONG, JAPON, NOUVELLE ZELANDE, OU AFRIQUE DU SUD. L'OFFRE N'EST PAS FAITE [...]
Trident Brands Inc. Entering US Hemp CBD Market with Brain Armor® R3 Supplement
12/10/2018
Brookfield, WI, Oct. 12, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Trident Brands Inc. (OTCQB: TDNT), a biotech and nutraceutical company, announces that Brain Armor® will launch a line of products that include CBD [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 septembre 2018
12/10/2018
Communiqué de presse Villepinte, le 12 octobre 2018 DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l' [...]
US Patent Trial & Appeal Board (PTAB) Upholds Silence Patent by Denying First of Five Patent Grant Review Applications Filed by Alnylam
12/10/2018
LONDON, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Silence Therapeutics plc, (AIM:SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious [...]
Silence Therapeutics Announces Receipt of a New European Notice of Intention to Grant a Patent and the Launch of an Interim European Injunction Application against Onpattro™
12/10/2018
LONDON, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Silence Therapeutics plc, (AIM:SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious [...]
Exagen Announces Launch of Novel Biomarker PC4d Associated with Thrombosis in Lupus
12/10/2018
Makers of the rapidly growing AVISE CTD test expands portfolio of patented CB-CAPs blood tests ALBUQUERQUE, NM and SAN DIEGO, CA, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Exagen Diagnostics, a leader in autoimmune life [...]
Radius Health to Announce Third Quarter 2018 Financial Results, Host Conference Call and Live Webcast on November 1, 2018
12/10/2018
WALTHAM, Mass., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 1, 2018. The Company will host a conference [...]
MPX Expands Maryland Footprint With Opening of Baltimore Dispensary
12/10/2018
TORONTO, Oct. 12, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“ MPX ” or the “ Company ”) (CSE: MPX; OTC: MPXEF) today announced that it opened its new Health for Life dispensary in Baltimore, Maryland which [...]
MRI Interventions and Monteris Medical Announce Collaboration to Develop Next-Generation Head Fixation Frames for Laser Ablation Neurosurgery
12/10/2018
IRVINE, Calif., Oct. 12, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) and Monteris Medical, Inc. today announced a collaborative co-development agreement to provide a next-generation head fixation frame [...]
Equillium Announces Pricing of Initial Public Offering
12/10/2018
LA JOLLA, Calif., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Equillium Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory [...]
Scythian Biosciences Applauds the UK Government’s Decision to Legalize Medical Cannabis
12/10/2018
Scythian’s Chief Medical Officer, The Famed Dr. Barnes, Receives National Praise for His Advocacy, Education and Tireless Leadership from Government, Media and Medical Organizations to Assist in Making This Major Event [...]
Foamix to Present Clinical Data From Study FX2017-22 at the Fall Clinical Dermatology Conference
12/10/2018
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and [...]
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $220 Million of Common Stock
12/10/2018
SAN CARLOS, Calif., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating [...]

Pages